Allogene Therapeutics (ALLO) Retained Earnings (2017 - 2026)

Allogene Therapeutics has disclosed Retained Earnings across 10 years of filings, most recently posting -$183000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$183000.0, down 525.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$183000.0 (down 525.58% YoY), and the FY2025 annual result was $269000.0, up 402.25% from the prior year.
• Retained Earnings came in at -$183000.0 for Q1 2026 at Allogene Therapeutics, down from $269000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $269000.0 in Q4 2025 to a low of -$2.0 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$1.1 billion (2022), against an average of -$945.1 million.
• Across the five-year window, Retained Earnings slumped 963425.74% in 2022 and surged 402.25% in 2025, its largest moves.
• Allogene Therapeutics' Retained Earnings stood at -$1.2 billion in 2022, then decreased by 26.5% to -$1.6 billion in 2023, then soared by 99.99% to -$89000.0 in 2024, then soared by 402.25% to $269000.0 in 2025, then plunged by 168.03% to -$183000.0 in 2026.
• The last three Retained Earnings figures came in at -$183000.0 (Q1 2026), $269000.0 (Q4 2025), and -$2.0 billion (Q3 2025), per Business Quant data.